3rd Annual Global Summit on Hematologic Malignancies: Europe
February 13 - 15, 2020
Oncology Meeting Innovations’ (OMI’s) 3rd Annual Summit on Hematologic Malignancies (Europe) fosters discussion and debate on the evolution of treatment of hematologic malignancies and features a focused approach towards individual patient populations through case-based discussions. In response to changes in the clinical landscape of chronic lymphocytic leukemia, multiple myeloma, lymphomas and acute leukemias, the summit assembles translational researchers, clinical researchers and key community oncologists to address the challenges of this rapidly evolving area of oncology. This event focuses on a European audience.
Program brochure available here.
- Examine how new agents targeting BTK, PI3K delta and BCL-2, as well as next-generation CD20 monoclonal antibodies are changing the landscape and treatment paradigms for CLL
- Identify treatment advances in multiple myeloma including recent data on drugs targeting CD38, SLAMF7, and HDAC in addition to novel approaches to proteasome inhibition
- Analyze advances in the understanding of the molecular biology and microenvironment in treating lymphoma and acute leukemia
- Discuss novel strategies such as chimeric antigen receptor T-cell therapy, checkpoint inhibition and next-generation antibody therapy in treating hematologic malignancies